1. Home
  2. Browse Decisions
  3. A.D.3d
  4. 182 A.D.3d
  5. 182 A.D.3d 506 (2020)
 

ERRANT GENE THERAPEUTICS, LLC v. SLOAN-KETTERING INSTITUTE

150856/17.

182 A.D.3d 506 (2020)

123 N.Y.S.3d 118

2020 NY Slip Op 02534

Errant Gene Therapeutics, LLC, Respondent, v. Sloan-Kettering Institute for Cancer Research et al., Appellants. Errant Gene Therapeutics, LLC, Respondent, v. Sloan-Kettering Institute for Cancer Research, Defendant, and Bluebird Bio, Inc., Appellant.

Appellate Division of the Supreme Court of New York, First Department.

Decided April 30, 2020.

In the early 2000's, defendant Sloan Kettering Institute for Cancer Research's (Sloan-Kettering) researcher, Dr. Michel Sadelain, developed an experimental gene therapy treatment for thalassemia using a recombinant "vector," i.e., a DNA molecule used as a vehicle to artificially carry foreign genetic material into another cell (the Sloan vector). In 2001, Sloan-Kettering filed for patent protection on the Sloan vector technology and was granted US Patent No. 7,541,179.

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases